The Diagnostic Value of Contrast-Enhanced Ultrasound Combined with Tumor Autoantibody Detection for Early Lung Cancer
Objective:To explore the diagnostic value of contrast-enhanced ultrasound quantitative analysis combined with 7 tumor autoantibody tests for early lung cancer.Methods:A total of 60 early-stage lung cancer patients in our hospital from October 2021 to October 2023 were collected as research subjects.Pathological diagnosis was used as the gold standard,and the diagnostic values of ultrasound contrast quantitative analysis,7 tumor autoantibody tests,ultrasound contrast quantitative analysis combined with 7 tumor autoantibody tests were analyzed.Results:Using pathological results as the gold standard,there were significant differences between the quantitative analysis of contrast-enhanced ultrasound and the detection of 7 tumor autoantibodies and pathological results.Joint detection diagnosis is superior to quantitative analysis of contrast-enhanced ultrasound and detection of 7 tumor autoantibodies,and more in line with alloy standards;The sensitivity and accuracy of combined application diagnosis are significantly higher than those of contrast-enhanced ultrasound quantitative analysis and 7 tumor autoantibody tests,with a significant difference in indicators(P<0.01).The cutoff value and sensitivity of combined diagnosis are the highest,with the lowest specificity and the highest area under the curve,which is significantly different from contrast-enhanced ultrasound quantitative analysis and 7 tumor autoantibody tests(P<0.05).Conclusion:The combination of contrast-enhanced ultrasound quantitative analysis and 7 tumor autoantibody tests has clinical application value for the early diagnosis of lung cancer.
contrast-enhanced ultrasoundquantitative analysistumor autoantibodiesjoint diagnosisearly stage of lung cancer
万方数据
维普
